Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could this new vaccine stop shingles for years?

NCT ID NCT07293065

Vaccine Sponsor: MAXVAX Biotechnology Limited Liability Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who develops shingles over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Recombinant Zoster Vaccine (CHO Cell) with adjuvant
What this could lead to
If successful, this vaccine could provide long-term protection against shingles for adults 40 and older, reducing pain and complications.
What could go wrong
This is a large Phase 3 trial, but results are not yet available. The vaccine may not prove effective over the full 3 years, and side effects like injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 12,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants in the MKKCT-100-003 study who have completed two doses of the investigational vaccine; 2. Males or females able to provide legal identity certificate; 3. Participants voluntarily agree to participate in the study, and sign the informed consent form; 4. Able to understand the study procedures and participate in all scheduled follow-up visits, and able to comply with the protocol requirements (such as cooperating in filling out questionnaires/scales, and being regularly contacted during the study for evaluation, etc.). Exclusion Criteria: 1. Participants who plan to use any products (drugs, vaccines, or medical devices) other than the investigational product for the prevention of VZV infection before signing the informed consent form or during the study period; 2. Participants with a history of herpes zoster; 3. Participants with any confirmed or suspected immunosuppressive or immunodeficiency condition caused by diseases (e.g., malignant tumors, human immunodeficiency virus infections, etc.) or immunosuppressive/cytotoxic treatments (e.g., medications used during cancer chemotherapy, organ transplantation, or treatment of autoimmune diseases); 4. Participants who are currently participating in or plan to participate in other clinical trials during the study; 5. Significant underlying diseases or any other condition that, in the opinion of the investigator, may prevent completion of the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster

Contacts and locations

Locations

  • Hebei Provincial Center for Disease Control and Prevention

    Shijiazhuang, Hebei, 050021, China

  • Henan Center for Diseases Control and Prevention

    Zhengzhou, Henan, 450016, China

  • Hubei Provincial Center for Disease Control and Prevention

    Wuhan, Hubei, 430070, China

  • Yunnan Center For Disease Control and Prevention

    Kunming, Yunnan, 650022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.